Objective: To evaluate the applicability of the main categories of risk and morphological factors in the prognosis of gastrointestinal stromal tumors.
Methods: we retrospectively studied fifty-four cases of GIST, assessing the main prognostic factors of this neoplasis: risk levels, topography, size, mitotic index, necrosis, histological subtype and immunophenotype. We also verified their association and the reduction of overall survival.
Results: Univariate analysis showed that tumors with mitoses number greater than 5 per 50CGA (high-power fields), the presence of necrosis and a high risk for both the systems proposed by Fletcher and Miettinen had a significant association with reduced survival (p = 0.00001, 0.0056, 0.03 and 0.009, respectively). The remaining analyzed factors (size, histological subtype, topography and immunophenotype) had no such association. Multivariate analysis (Jacard index) showed that the Miettinen degree of risk was the one that best correlated with prognosis.
Conclusion: the risk criteria of Fletcher and Miettinen are important in assessing the prognosis of patients with gastrointestinal stromal tumors, especially the latter, which adds to the mitotic index and the presence of tumor necrosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/0100-69912015001007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathological analysis of anti-VEGF drug-associated renal thrombotic microangiopathy: A case series and review of the literature.
Pathol Res Pract
January 2025
Department of Pathology, West China Hospital of Sichuan University, Chengdu 610041, China.
Anti-vascular endothelial growth factor-associated thrombotic microangiopathy (aVEGF-TMA) was recently discovered in patients with malignant tumors. Four aVEGF-TMA patients diagnosed by renal biopsy between 2018 and 2022 were identified, and all were females aged 30-62 years (mean age, 47 years). Two patients with malignant gastrointestinal stromal tumors who received sunitinib were analyzed.
View Article and Find Full Text PDFGastrointestinal stromal tumor mimicking a gynecologic mass.
Int J Gynecol Cancer
January 2025
University of Magdalena, Women's Medicine Department, Faculty of Medicine, Santa Marta, Colombia. Electronic address:
Imatinib-induced hard palate mucosal discoloration in patients with gastrointestinal stromal tumour (GIST) and dermatofibrosarcoma protuberans (DFSP): a case series of three patients and literature review.
Postepy Dermatol Alergol
December 2024
Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Synchronous gastric adenocarcinoma and gastrointestinal stromal tumour.
ANZ J Surg
January 2025
Department of General Surgery, Te Whatu Ora, Health New Zealand, Waitemata, New Zealand.
Gastric schwannoma with post-surgical gastroparesis: a case report and literature review.
Front Oncol
January 2025
Central Laboratory, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Gastric schwannoma is a relatively rare submucosal mesenchymal tumor with low probability of metastasis and arises from Schwann cells of the gastrointestinal nervous plexus. Surgical therapy is the main treatment of gastric schwannoma with symptoms or malignant tendency. Gastroparesis is a potential complication following gastrointestinal surgery, which is a clinical syndrome caused by gastric emptying disorder and characterized by nausea, vomiting, and bloating, resulting in insufficient nutrient intake.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!